Skip to content
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · MID CAP

Outset Medical, Inc. OM

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$119.5M
▲ 5.1% YoY
$-81.7M
$-47.1M
In brief

What this company does

Outset Medical, Inc. manufactures its Tablo consoles and a substantial majority of Tablo cartridges at its manufacturing facility in Tijuana, Mexico. Tablo is cleared by the U.S. Food and Drug Administration for use in the hospital, clinic or home setting. The company sells Tablo to dialysis clinic operators, which in turn provide equipment and services to the patient and are reimbursed by Medicare, Medicaid, and other third-party payors. The company has experience helping nearly 1,000 acute-care facilities. As of December 31, 2025, it had 310 full-time employees, with 58% in its field sales and service teams and 42% in the rest of the company. As of December 31, 2025, its manufacturing facility in Tijuana, Mexico had 254 full-time team members on-site across quality, engineering, manufacturing, supply chain, and other support functions.

Written from the business description in Outset Medical, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 13 February 2026. Every sentence was checked against that document before publication.

Growth
USD 119.5M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 119.5 · Net income -81.7
50M100M-80M-160M20182019202020212022202320242025
Compound annual growth
+1.2%
+19.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +19.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−68 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -55.8% · Net -68.3%
-1000%-2000%20182019202020212022202320242025
ROE
FY2025 · ROE -106.2%
-50%-100%-150%20182019202020212022202320242025

Each USD of equity lost 106 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -47.1
-80M20182019202020212022202320242025

Total assetsUSD 264.5M
EquityUSD 127.0M
CashUSD 35.0M
Gross debtUSD 96.2M
Net debtUSD 61.2M
Current ratio6.67×

Net debt stands at 48% of equity.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018
Revenue $B0.10.10.10.10.10.00.00.0
Operating income $B−0.1−0.1−0.2−0.2−0.1−0.1−0.1−0.0
EBITDA $B−0.1−0.1−0.2−0.2−0.1−0.1−0.1−0.0
Income tax $B0.00.00.00.00.00.00.00.0
Net income $B−0.1−0.1−0.2−0.2−0.1−0.1−0.1−0.0
Free cash flow $B−0.0−0.1−0.1−0.2−0.1−0.1−0.1−0.0
EPS, diluted $−5.37−36.96−52.28−3.38−2.89−4.85−99.58−100.75
Dividend / sh $········
Payout %········
ROE %−106.2−171.0−93.7−52.6−37.6···
Shares out B0.020.000.050.050.050.040.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 3 failures in 38 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 57 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image